When examining the FDA’s testing report, something else stood out to Havens.

“Interestingly, FDA tested for 11 different cannabinoids, including lesser-known, ‘minor’ cannabinoids like CBG and CBN,” he says. “This shows they aren’t just focused on CBD” or even THC, the primary psychoactive ingredient in cannabis.

The FDA isn’t alone: Recreational marijuana dispensaries are touting 27 different “secondary cannabinoids” on product packaging, per BDSA. “Tracking what’s happening in the dispensary channel is a good indication of where things will go next,” Lukas says, specifically citing cannabigerol (CBG), cannabinol (CBN), Tetrahydrocannabinolic acid (THCA) and tetrahydrocannabivarin (THCV) as the four most prominent cannabinoids after THC and CBD.

Patterson of MartketHub anticipates that, as mainstream consumers become more educated on the total cannabis experience, the opportunities will only grow. “CBD is just the tip of the spear,” he says. “What this stuff does, the way those cannabinoids behave with the body, it’s extraordinary.”